• Ulf Boberg, PhD, who joined Affibody (Stockholm, Sweden) in January 2006 as senior vice president development, replaces as CEO Dr. Carl-Johan Dalsgaard who has been acting CEO of Affibody since December 2005. Dalsgaard is a partner of Affibody's largest shareholder HealthCap and will remain a non-executive board member of Affibody. Most recently, Boberg was CEO of Global Genomics. Affibody is a life sciences company focusing on oncology.

• Gregory Keane, executive vice president, CFO and treasurer of BioScrip (Elmsford, New York) will leave the company on June 9. Keane became BioScrip's CFO when MIM acquired Chronimed in March 2005. The company subsequently changed its name to BioScrip. Prior to the merger, Keane had served as Chronimed's CFO since 1999. Pending the selection of a permanent replacement, the company's senior financial team will assume all day-to-day responsibilities. BioScrip provides comprehensive pharmaceutical care solutions.

• James Agnello will join Clarient (Aliso Viejo, California) as senior vice president and CFO, effective June 19. Agnello replaces Jay Roberts, who has been serving as Clarient's interim CFO since February 2006. Agnello most recently served as controller and chief accounting officer and division CFO at Teleflex. Clarient provides technologies, services and the critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process.

• Marc Larsen has been appointed chief operating officer for the Health Technology Center (HealthTech; San Francisco). Larsen comes to HealthTech from Salem Hospital Regional Health Services where he was vice president of strategy and business development. HealthTech is a non-profit research and education organization that develops objective forecasts, decision-making tools and facilitates a learning network of experts for healthcare systems, hospitals, safety-net providers and government agencies.

• Uroplasty (Minnetonka, Minnesota) reported the June 1 passing of Daniel Holman, chairman of the board since 1994. He served as president and CEO from 1994 to 2004. Under Holman's leadership, Uroplasty evolved from selling a single product outside the U.S. to a diversified company with products sold globally to treat voiding dysfunctions.